Premium
A novel Gymnema sylvestre extract stimulates insulin secretion from human islets in vivo and in vitro
Author(s) -
AlRomaiyan A.,
Liu B.,
AsareAnane H.,
Maity C. R.,
Chatterjee S. K.,
Koley N.,
Biswas T.,
Chatterji A. K.,
Huang GC.,
Amiel S. A.,
Persaud S. J.,
Jones P. M.
Publication year - 2010
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.3125
Subject(s) - gymnema sylvestre , in vivo , insulin , endocrinology , medicine , diabetes mellitus , in vitro , type 2 diabetes , pharmacology , islet , secretion , type 2 diabetes mellitus , biology , traditional medicine , biochemistry , microbiology and biotechnology
Many plant‐based products have been suggested as potential antidiabetic agents, but few have been shown to be effective in treating the symptoms of Type 2 diabetes mellitus (T2DM) in human studies, and little is known of their mechanisms of action. Extracts of Gymnema sylvestre (GS) have been used for the treatment of T2DM in India for centuries. The effects of a novel high molecular weight GS extract, Om Santal Adivasi, (OSA®) on plasma insulin, C‐peptide and glucose in a small cohort of patients with T2DM are reported here. Oral administration of OSA® (1 g/day, 60 days) induced significant increases in circulating insulin and C‐peptide, which were associated with significant reductions in fasting and post‐prandial blood glucose. In vitro measurements using isolated human islets of Langerhans demonstrated direct stimulatory effects of OSA® on insulin secretion from human ?‐cells, consistent with an in vivo mode of action through enhancing insulin secretion. These in vivo and in vitro observations suggest that OSA® may provide a potential alternative therapy for the hyperglycemia associated with T2DM. Copyright © 2010 John Wiley & Sons, Ltd.